OOIR: Observatory of International Research

Papers

(The TQCC of Hematology-American Society of Hematology Education Program is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Managing toxicities of Bruton tyrosine kinase inhibitors	82
Therapeutic development and current uses of BCL-2 inhibition	71
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors	42
Preventing infections in children and adults with asplenia	42
Platelet transfusion refractoriness: how do I diagnose and manage?	41
Monoclonal gammopathies of clinical significance	39
Bispecifics, trispecifics, and other novel immune treatments in myeloma	39
Updates in infection risk and management in acute leukemia	37
Gene therapy for hemophilia	35
Therapy for lower-risk MDS	34
Management of AL amyloidosis in 2020	32
Updates in chronic graft-versus-host disease	30
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes	30
Inferior vena cava filters: a framework for evidence-based use	28
Next-generation cell therapies: the emerging role of CAR-NK cells	27
Does ABO and RhD matching matter for platelet transfusion?	26
Dyskeratosis congenita and telomere biology disorders	24
Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review	23
Have we reached a molecular era in myelodysplastic syndromes?	23
Management of Waldenström macroglobulinemia in 2020	23
Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management	22
Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics	22
Future of CAR T cells in multiple myeloma	22
Outpatient transfusions for myelodysplastic syndromes	22
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia	22

Antibodies and bispecifics for multiple myeloma: effective effector therapy	21
Modern management of Fanconi anemia	21
Advances in the management of α-thalassemia major: reasons to be optimistic	21
“TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry	21
Combining antiplatelet and anticoagulant therapy in cardiovascular disease	21
Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic di	20
Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?	20
What to use to treat AML: the role of emerging therapies	19
Allogeneic hematopoietic cell transplantation for older patients	19
Management of heavy menstrual bleeding on anticoagulation	18
Gene therapy for sickle cell disease: where we are now?	18
Optimizing the management of chronic pain in sickle cell disease	17
First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?	17
Women and bleeding disorders: diagnostic challenges	17
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	17
High-risk multiple myeloma: how to treat at diagnosis and relapse?	17
Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes	17
Indications for transfusion in the management of sickle cell disease	16
Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)	16
Identifying potential germline variants from sequencing hematopoietic malignancies	16
How to avoid the problem of erythrocyte alloimmunization in sickle cell disease	16
Approach to the patient with suspected hypereosinophilic syndrome	16
Cellular therapy for multiple myeloma: what's now and what's next	15
Double-hit lymphoma: optimizing therapy	15
Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings	15
Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management	15
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms	15
Does aspirin prevent venous thromboembolism?	15
How do we sequence therapy for marginal zone lymphomas?	15
Mechanisms of somatic transformation in inherited bone marrow failure syndromes	15
Epidemiology and treatment of priapism in sickle cell disease	15
Chemotherapy-free frontline therapy for CLL: is it worth it?	15
Blast and accelerated phase CML: room for improvement	14
How to recognize and manage COVID-19-associated coagulopathy	14
Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop	14
Transformed lymphoma: what should I do now?	14
Evidence-Based Minireview: Abnormal uterine bleeding in users of rivaroxaban and apixaban	14
Hemophilia gene therapy: ushering in a new treatment paradigm?	14
Challenges in chronic transfusion for patients with thalassemia	14
How to manage CML patients with comorbidities	14
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	13
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	13
Relapsed ALL: CAR T vs transplant vs novel therapies	13
Treatment of Richter's syndrome	13
Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs	12
Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?	12
Diamond-Blackfan anemia	12
Global look at nutritional and functional iron deficiency in infancy	12
Inherited microcytic anemias	12
Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP	12

Heparin-induced thrombocytopenia and cardiovascular surgery	12
Sequencing therapy in relapsed DLBCL	11
Genomics of MPN progression	11
In 2022, which is preferred: haploidentical or cord transplant?	11
Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency	11
Sequencing multiple myeloma therapies with and after antibody therapies	11
How to evaluate and treat the spectrum of TMA syndromes in pregnancy	11
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	11
Molecular prognostication in Ph-negative MPNs in 2022	11
When does a PNH clone have clinical significance?	11
Extrahematopoietic manifestations of the short telomere syndromes	11
Direct oral anticoagulant (DOAC) interference in hemostasis assays	11
COVID-19 and thrombosis: searching for evidence	11
Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life	10
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation	10
Transplant for TP53-mutated MDS and AML: because we can or because we should?	10
Lower risk but high risk	10
When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?	10
Achieving MRD negativity in AML: how important is this and how do we get there?	10
How immunodeficiency can lead to malignancy	10
Hematology 2022—what is complete HLA match in 2022?	10
Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas	10